Drug Pipeline

Taletrectinib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
2
Phase 3
1
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-20 NCT07154706
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC…		 Trial sites expanded: 29 -> 33 locations
Active Studies by Phase
Phase 3
2
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06564324 A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally… Non Small Cell Lung Cancer Recruiting
NCT07154706 Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC… Non-small Cell Lung Cancer (NSCLC) Recruiting
Phase 2
NCT04919811 Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Non Small Cell Lung Cancer Active, Not Recruiting
NCT04395677 A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene Non Small Cell Lung Cancer Active, Not Recruiting
Sponsors Running Taletrectinib Trials
Nuvation Bio Inc. (4)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (4) Lung Cancer (4)
Get alerts when Taletrectinib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free